Delisting risk
GOSS · NASDAQ · Biotechnology

Gossamer Bio

Develops inhaled seralutinib for pulmonary arterial hypertension and PH-ILD.

$0.1726
After-hours close+0.00 (+2.49%)
At close$0.1684(−1.00%)
DateEstimateReportedSurprise
Nov 2026−$0.07
Aug 2026−$0.12−$0.08+35.2%
May 2026−$0.17−$0.20−17.6%
Mar 2026−$0.20−$0.21−5.0%
Nov 2025−$0.19−$0.21−10.5%

The latest year is open to everyone — the 34 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Mar 2022
Nov 2021
Aug 2021
May 2021
Feb 2021
Nov 2020
Aug 2020
May 2020
Mar 2020
Nov 2019
Aug 2019
May 2019
Mar 2019
Feb 2019
Jun 2018
Mar 2018
Dec 2017
Sep 2017
Jun 2017
Mar 2017
Report dateEPS estEPSSurpriseRevenue estRevenueSurprise
Nov 4, 2026−$0.07$10.7M
Aug 13, 2026−$0.12−$0.08+35.2%$3.6M$9.2M+154.6%
May 18, 2026−$0.17−$0.20−17.6%$4.7M$17.0M+263.2%
Mar 17, 2026−$0.20−$0.21−5.0%$7.5M$13.8M+83.4%
Nov 5, 2025−$0.19−$0.21−10.5%$7.5M$13.3M+76.6%

The latest year is open to everyone — the 34 quarters behind it read with an account.

Sign in
Aug 5, 2025
May 15, 2025
Mar 13, 2025
Nov 7, 2024
Aug 12, 2024
May 7, 2024
Mar 5, 2024
Nov 9, 2023
Aug 8, 2023
May 9, 2023
Mar 17, 2023
Nov 3, 2022
Aug 9, 2022
May 10, 2022
Mar 3, 2022
Nov 8, 2021
Aug 9, 2021
May 6, 2021
Feb 25, 2021
Nov 10, 2020
Aug 11, 2020
May 12, 2020
Mar 24, 2020
Nov 12, 2019
Aug 8, 2019
May 14, 2019
Mar 22, 2019
Feb 12, 2019
Jun 30, 2018
Mar 31, 2018
Dec 31, 2017
Sep 30, 2017
Jun 30, 2017
Mar 31, 2017